To clarify the role of PDGF A-chain in hypertensive vascular hypertrophy of spontaneously hypertensive rats (SHRs), we studied levels of PDGF A-chain gene expression and transcription factors related to the gene in vascular smooth muscle cells (VSMCs) of SHRs in vivo. RNase protection assay and in situ hybridization showed that PDGF A-chain mRNA levels in VSMCs of SHRs were twofold higher than in those of normotensive Wistar-Kyoto rats. Gel retardation assays showed that levels of Spl and AP-2 in VSMCs of SHRs were twofold more abundant than in those of WistarKyoto rats. Treatment with four pharmacologically different species of antihypertensive drugs for 2 wk decreased the levels of both PDGF A-chain mRNA and Spl, but not AP-2 level in VSMCs of SHRs with regression of aortic hypertrophy, indicating that increases in levels of both PDGF Achain mRNA and Spl in VSMCs of SHRs were associated with high blood pressure. These results suggest that high blood pressure is a stimulus which upregulates PDGF Achain gene expression in VSMCs of SHRs, resulting in an autocrine enhancement in hypertensive vascular hypertrophy, and that the activation of the gene may be mediated through increases in Spl in these cells. (J. Clin. Invest. 1995Invest. . 95:1140Invest. -1150
Introduction
Hypertensive vascular hypertrophy is a major pathological change in blood vessels after chronic exposure to high blood 1 . Abbreviations used in this paper: All angiotensin II; Egr-1, early growth response; G6PD, glucose-6-phosphate dehydrogenase; GC factor, guanosine cytidine-rich sequence binding factor; PDGF-AA, dimer of PDGF A-chain; RT-PCR, reverse transcription-PCR; SD, SpragueDawley; SHR, spontaneously hypertensive rat; SRF, serum response factor; SSRF, shear stress response factor; TBP, TATA box binding protein; VSMC, vascular smooth muscle cell; WKY, Wistar-Kyoto. pressure, and is characterized by the hypertrophy of vascular smooth muscle cells (VSMCs)' (1) (2) (3) . Vascular hypertrophy stimulates arteriosclerosis of vessel walls, resulting in acceleration of hypertension due to elevation of arterial resistance and also in progress of atherosclerosis in systemic vessels.
The molecular mechanism by which high blood pressure causes hypertensive vascular hypertrophy in VSMCs has not yet been determined. Although antihypertensive treatments can reduce hypertensive vascular hypertrophy, up to 6 yr of antihypertensive treatment may be necessary to achieve normal vascular structure in patients with essential hypertension (4) . There- fore, understanding the mechanisms of hypertensive vascular hypertrophy may allow the development of novel therapeutic approaches for the prevention of hypertensive vascular injury and the progress of atherosclerosis in hypertensive patients.
It has been suggested that numerous cellular growth regulatory molecules, in particular PDGF, are responsible for the migration, proliferation, and formation of connective tissue by VSMCs in vitro (5, 6) . Recent studies (7) (8) (9) (10) showed that antisense PDGF A-chain oligonucleotides and antibodies to PDGF A-chain inhibited growth of cultured VSMCs by potent growth factors, IL-1, IL-6, angiotensin II (A II), and TGF-,/, indicating that the proliferation-inducing activities of these factors are mediated by autocrine secretion of a dimer of PDGF A-chain (PDGF-AA) in cultured VSMCs. Thus, PDGF-AA may be an important peptide for proliferation of VSMCs and a candidate growth regulatory molecule for the hypertrophy of VSMCs in hypertension.
PDGF is an 28-35 kD peptide which is present in platelets and is secreted from VSMCs, endothelial cells, macrophages, and fibroblasts (5, 11) . PDGF is composed of two closely related but nonidentical protein subunits, PDGF A-chain and Bchain, which form three possible dimeric configurations; AA, BB, and AB. All three forms of PDGF are mitogenic by binding to specific high-affinity cell surface receptors on mesenchymal cells such as VSMCs, fibroblasts, astrocytes, and osteoblasts (5) . PDGF receptors consist of combinations of two different subunits, a-and ,/-receptors, which dimerize to form three distinct receptors; aa, a/3, and /,3. According to the ligand specificity of the receptors, PDGF-AA binds aa receptor, PDGF-AB, aa, or a/3 receptor, and PDGF-BB, a/3, or /B receptor ( 12) . The relative biological activity (mitogenicity and chemotactic activity) depends upon both the isoform of PDGF dimer and the relative number of a-and /-receptor subunits on the cell surface (12, 13) . In vivo, normal VSMCs constitutively express small amounts of PDGF A-chain mRNA, produce homodimeric PDGF-AA, and evidently express PDGF a-and /3-receptors (12, 14) , while they rarely express PDGF B-chain mRNA or PDGF B-chain peptide, and PDGF B-chain mRNA is only detected in atherosclerotic lesions (15, 16) .
Spontaneously hypertensive rats (SHRs) are a useful ge-netic animal model of human essential hypertension, in which systolic pressure at 10 wk is elevated up to 160 mmHg, and aortas of SHRs show typical hypertensive vascular hypertrophy after 12 wk of age (17) . Recent studies (18, 19) Cloning and identification of PDGF A-chain and glucose-6-phosphate dehydrogenase (G6PD) cDNAs. Cloning of PDGF A-chain and G6PD cDNAs was performed by insertion of PCR products into cloning expression vectors (20, 21) . Oligonucleotide primers were synthesized with an automatic DNA synthesizer (Applied BioSystems, Inc., Tokyo, Jaean). Primers were identical to the 5'-end (5'-AAGCATGTGCCG-GAGAAGCG-3') and complementary to the 3'-end (5'-GTCCAG-GTGAGGTTAGAGGA-3') of the coding region of rat PDGF A-chain cDNA (22) , and identical to the 5 '-end (5 '-GAGGACCAGATCTAC-CGCAT-3') and complementary to the 3 '-end (5'-GTCCGTGAT-GAGAAGGTCAA-3') of the coding region of rat G6PD cDNA (23 (26) . After incubation for 60 min at 370C, 0.5 nM each of ATP, GTP, CTP, and UTP and 5 U of T7 RNA polymerase were added to the mixture for elongation of the radiolabeled riboprobe to the full length. After incubation for 60 min at 37°C, 1 Ag RNasefree DNase (Takara Shuzo Co.) was added to the mixture and incubated for 15 min at 37°C. The samples were electrophoresed through 4% polyacrylamide/8 M urea gels which were then exposed to XAR x-ray film. The gel fragment at the positive signal was excised and the riboprobe was eluted by overnight incubation at 37°C in 0.5 M sodium acetate (pH 5.0) and 1 mM EDTA (27) In situ hybridization. In situ hybridization was performed by a slight modification of the method described previously (28) . Briefly, tissues were immediately immersion fixed in phosphate buffer containing 4% paraformaldehyde for 2 h, cryoprotected, and cut into 6-;tm frozen sections which were thaw mounted onto poly-L-lysine subbed slides. After treatment with proteinase K and acetylation of amino groups by acetic anhydride, sections were prehybridized in 2 x SSC buffer containing 50% deionized formamide, 100 tcg/ml denatured salmon sperm DNA, 10 x Denhardt's solution (0.2% Ficoll 400, 0.2% polyvinylpyrrolidone, and 0.2% BSA), 0.1% SDS, and 10 mM DTT, and hybridized in fresh identical solution containing the 35S-labeled PDGF A-chain antisense RNA probe at 42°C overnight. After DNase-free RNase treatment (25 ug/ml) for 30 min at 37°C and washings up to 0.1 x SSC at 42°C, slides were dipped in photographic emulsion (Fuji Film Inc., Tokyo, Japan) and exposed for 3 d at 4°C. Sections were developed, counterstained with hematoxylin, and observed by light microscopy. Control slides were incubated with sense riboprobe of a similar specific activity. 35S-labeled PDGF A-chain antisense RNA and sense RNA were synthesized by incubation of the linearized plasmid templates with [a-35S]UTP. These riboprobes were labeled to a sp act of 0.3 x 10' dpm/ug. Reverse-transcription polymerase chain reaction (RT-PCR) assay. The amounts of RNA in the aortic medial layer of individual animals were too low (-1.5 /ug) to allow detection of PDGF A-chain mRNA by RNase protection assay. To overcome this problem, we established a quantitative RT-PCR assay for the detection of PDGF A-chain mRNA in individual aortic medial layers as previously described (21) .
The same primers and the same thermal cycle profile of PCR were used as described above. To confirm the specificity of the method and to reduce the number of PCR cycles, the PCR products were detected by Southern blot hybridization with radiolabeled oligonucleotide probes specific for each cDNA. Briefly, aliquots (250 ng/20 .LI) of RNA were reverse-transcribed to single-stranded cDNA and amplified by PCR. To improve the accuracy of the amplification of mRNA (21) , these procedures were performed at the same time and under the same conditions. Aliquots (5 tl) of PCR products were dot blotted onto nylon membranes (Hybond-N Plus; Amersham Japan, Inc.), and fixed by ultraviolet irradiation ( 120 mJ/cm2). The blotted membranes were prehybridized in a solution containing 2 x sodium chloride sodium phos- (26) . Hybridized membranes were washed twice for 30 min at a stringency of 1 x sodium chloride sodium phosphate with 0.1% SDS at the calculated melting temperature -10°C (26) . Autoradiography was performed for 3 h at room temperature with an intensifying screen, and scanning densitometry was used to give quantitative data. Assays were performed in duplicate. A no-cDNA control was always used as a negative control and G6PD mRNA in the samples was used as an internal control to confirm that mRNA in each sample was equally amplified. The sequence for the oligonucleotide probe specific for amplified G6PD cDNA was 5 '-ATCCTGTrGGCAAATCTCAGCAC-3'. Gene expression was expressed as the ratio of signal intensities for PDGF A-chain to G6PD on autoradiograms.
Oligonucleotide probes for gel retardation assays. Since a recent report (29) indicated that both nucleotide sequence and structure of the promoter region of PDGF A-chain gene are highly conserved in human and mouse, we expected the promoter region of the rat PDGF A-chain gene to also be highly conserved. Seven transcription factors were selected from the DNA consensus motifs in the promoter region of the human PDGF A-chain gene ( Fig. 1) (30, 31 ) . In the 5 '-flanking region of the gene, there are a TATA box, eight Spl sites, two early growth response-1 (Egr-1) sites, an AP-2 site, guanosine cytidine-rich sequence binding factor (GC factor) site, a serum response element, and a shear stress responsive element (32) (33) (34) (35) (36) (37) (38) . According to recent reports, proteins including TFHD complexes binding to the TATA box are referred to as TATA box binding proteins (TBP), proteins binding to the serum response element; serum responsive factor (SRF), and proteins binding to the shear stress responsive element; shear stress response factor (SSRF).
The sequences of oligonucleotides used in the present study are depicted in Table I . The Spl site in the Egr-I consensus sequence was deleted to exclude false binding of Spl to the Egr-I probe. Each sense oligonucleotide was radiolabeled to a sp act of 7 x 106 dpm/pM by 5' end-labeling method as described above. Aliquots of sense and antisense oligonucleotides were boiled for 3 min in a solution containing 10 mM Tris-HCl (pH 7.6), 50 mM NaCl, and 1 mM EDTA for 3 min and slowly cooled to room temperature to allow annealing.
Gel retardation assays. Cellular extracts from aortic medial layers were used in the gel retardation assays, because aortic medial layers were too stiff and small to obtain enough numbers of nuclei for assays Gel retardation assays were performed as previously described (39) . Briefly, a constant DNA amount of histone-depleted cellular extract (50 ng of DNA, equivalent to -1.6 x 104 mammalian nuclei [25] ) was incubated in 20 pd of a reaction mixture containing 50 mM Hepes-KOH (pH 7.6), 50 mM KCI, 1 mM DTT, 0.5 mM EDTA, 1% glycerol, 0.5 mM PMSF, 1 tsg of nonspecific DNA (pBR322 plasmid), and 2 ug of poly(dl-dC) poly(dl-dC). In the assay for measurement of TBP, poly(dG-dC) -poly (dG-dC) were used instead of poly(dl-dC) * poly(dl-dC). The 32P-labeled DNA probe (30 
Results
Blood pressure, heart rate, and hypertrophy index. The systolic blood pressure of 14-wk-old SHRs was significantly higher than those of normotensive WKY and SD rats (both P < 0.01; Table  II ). Treatment with antihypertensive drugs for 2 wk lowered blood pressure levels in SHRs (P < 0.01, respectively). As expected, nicardipine and hydralazine treatment increased heart rate of SHRs, but other drug treatments did not. Increases in body weight of rats (-40 g) were observed in all groups for 2 wk. The levels of hypertrophy index in control SHRs were higher than those in age-matched WKY and SD rats (both P < 0.05) and in SHRs treated with antihypertensive drugs (P < 0.05).
In situ hybridization histochemistry of PDGF A-chain mRNA in aortic medial layers. Microscopic examination of hematoxylin eosin-stained cross-sections of thoracic aortas at 14 wk of age showed medial thickening of aortas in SHRs and that VSMCs of the medial layers were hypertrophied as reported previously ( 1) .
In situ hybridization histochemistry showed positive silver grain deposition indicating PDGF A-chain mRNA in the aortic medial layers (Fig. 2) , and a small number of grains were also observed in the adventitial cells. In contrast, a minimal amount of silver grains, consistent with nonspecific background staining, was observed in tissue incubated with the labeled sense probe, indicating that the positive signals were specific for PDGF A-chain mRNA. Amounts of silver grains per nucleus in aortic medial layer of SHRs were greater than in those of WKY rats (P < 0.05 by Mann-Whitney U-test), indicating that the increased level of PDGF A-chain mRNA detected in the RNase protection assay was located in VSMCs.
Evaluation of RNase protection assays. RNase protection assay for PDGF A-chain mRNA in VSMCs of aortic medial layers showed a single protected fragment (Fig. 3) , indicating that the specificity of the assay was sufficient to detect mRNA in the tissue. RNase protection assay for G6PD mRNA also showed a single protected band in total RNA from VSMCs. To examine the linearity between amount of RNA loaded and densitometric intensity of RNase-protected bands, the dose-dependency of PDGF A-chain mRNA in the assay was investigated. As shown in Fig. 4 35 cycles, and the amounts of PCR products were analyzed by dot blot analysis. To avoid the saturated exposure of x-ray film, we performed multiple short exposures. In a 3-h exposed autoradiogram, the results of RT-PCR from 0 to 500 ng of RNA for [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] cycles showed good linearity between amount of RNA and intensity of autoradiograms (Fig. 5) . From these results, we selected 25 cycles of PCR for the quantification of PDGF Achain mRNA in the tissue. By the same approach as described above, 23 cycles of PCR for G6PD mRNA was used in the present study. The intraassay variation of the assay was 11% (n = 5).
Correlation of PDGF A-chain mRNA in vascular smooth muscle cells with levels ofboth bloodpressure and aortic hypertrophy index. To examine the relationship between blood pressure and PDGF A-chain mRNA levels in VSMCs of SHRs, we investigated the effects of treatment with two different doses of enalapril (10 and 25 mg/kg per d) on gene expression in VSMCs using the RT-PCR assay. Because PDGF A-chain Figure 5 . Linearity between number of PCR cycles and amount of RNA samples in RT-PCR assay for PDGF A-chain mRNA. 125, 250, and 500 ng of total RNA from the aortic medial layer were reverse-transcribed and PDGF A-chain mRNA was amplified by PCR with the indicated numbers of cycles. Each sample was analyzed by dot blot hybridization and data was plotted as the mean±SE of densitometric counts of the autoradiograms (n = 3, respectively).
mRNA and blood pressure levels were not distributed as the standard normal distribution, Spearman's rank correlation test was used for analysis. There was a good correlation between blood pressure and PDGF A-chain mRNA levels in VSMCs of SHRs (rs = 0.81, P < 0.001; Fig. 6 A) , indicating that PDGF A-chain gene expression in VSMCs of SHRs is associated with blood pressure level. This result supports those of the RNase protection assay. There was a good correlation between levels of PDGF A-chain mRNA in VSMCs and hypertrophy index in SHRs (rs = 0.74, P < 0.005; Fig. 6 B) , indicating that PDGF A-chain mRNA levels were associated with the extents of hypertensive vascular hypertrophy of VSMCs in these animals. Treatment with other antihypertensive drugs also showed a good correlation between levels of PDGF A-chain mRNA and blood Evaluation ofgel retardation analysis. To examine the relationship between amount of SpI and intensity on autoradiogram, we prepared five step-diluted samples by serial dilutions of cellular extracts of VSMCs of SHRs with extraction buffer and applied these to the assay. The retarded bands which were diminished after coincubation with 25-fold excess cold competitors were considered to be specific protein-oligonucleotide complex signals. As shown in Fig. 7 , there was a good linear relationship between the amount of extracts and densitometric intensity of retarded bands (r = 0.95, P < 0.05). Evaluating experiments with other transcription factors showed the-similar results. We routinely applied each sample containing 50 ng of DNA, equivalent to 1.6 x 104 nuclei (26) , to all assays. Two cycles of freezing and thawing or keeping overnight at 4°C did not affect the results. The intraassay variation of the assay was 15% (n = 5).
Levels of transcription factors in vascular smooth muscle cells. As shown in Fig. 8 , all transcription factors except SSRF were identified by the assays, although their signal intensities differed greatly. From the exposure times required to obtain each retarded signal, Sp 1, AP-2, and Egr-1 were more abundant in VSMCs than TBP, SRF, or GC factor. The levels of SSRF were very low in VSMCs and difficult to study (data not shown). Results on AP-2 showed the presence of two bands as previously reported, and it has been suggested that the proteins binding to each consensus sequence may be polymerized, complexed, or belonging to a transcription factor family (18, 35) . Levels of both SpI and AP-2 in VSMCs of SHRs were increased to 201 and 183% of the respective levels in WKY rats. There were almost no differences in the levels of other transcription factors, especially in early growth response gene products Egr-1 and SRF (37), between the two rat strains.
Effects of antihypertensive treatments on transcription factors in vascular smooth muscle cells. To determine whether the observed changes in transcription factor levels in VSMCs of SHRs are caused by high blood pressure or genetic background of the strains, we investigated the effects of antihypertensive treatments in vivo. The results showed that after treatment with four pharmacologically different species of antihypertensive drugs for 2 wk, Spl levels in VSMCs of SHRs decreased approximately to the same level as in that of WKY rats, with a concomitant decrease in PDGF A-chain mRNA levels (n = 3, P < 0.05; Fig. 9 ). The decreases in Spl and PDGF A-chain mRNA in VSMCs were also observed after enalapril treatment for 4 wk (data not shown), indicating that these changes were not merely transient cellular responses and that blood pressure levels modulated Spl levels in VSMCs of SHRs. In contrast, the amount of AP-2 in VSMCs of SHRs was almost unchanged after antihypertensive treatments (Fig. 10) , indicating that increases in AP-2 levels in VSMCs of SHRs are not associated with blood pressure levels but may be caused by the differences in genetic background of the rat strains.
In addition, SRF levels in VSMCs of SHRs were decreased after enalapril treatment for 2 wk (n = 3, P < 0.05; Fig. 10 
Discussion
The present study demonstrated that PDGF A-chain mRNA levels are increased in hypertrophic VSMCs of SHRs in vivo, and that PDGF A-chain gene expression in these cells is associated with levels of both blood pressure and vascular hypertrophy in SHRs. Gel retardation analysis showed that an increase in Spl in VSMCs of SHRs was associated with an increase in PDGF A-chain mRNA induced by high blood pressure in these cells.
We showed that VSMCs from aortic medial layers of adult rats evidently contained PDGF A-chain mRNA by three differ- (3, 14, 15) . However, these findings differ significantly from the results of Sarzani et al. (42, 43) who reported that PDGF A-chain mRNA levels in rat aortas were too low to study between strains. Although the reason for this difference is unclear, it is possible that (a) the sensitivities of the assays in the former studies including ours were higher than that of Sarzani et al., and (b) the samples used by Sarzani et al. may have been contaminated with adventitial tissue because their samples contained PDGF B-chain mRNA, which is never expressed in VSMCs, but is strongly expressed in aortic adventitial tissue ( 14) . We demonstrated that PDGF A-chain mRNA level was approximately twofold higher in hypertrophic VSMCs of SHRs than in those from normotensive WKY rats. A previous in vitro study (44) showed that a genetic background of SHRs may affect autocrine production of growth factors in cultured VSMCs, when these cells are stimulated. Therefore, to determine whether the increase in PDGF A-chain gene expression in vivo in VSMCs of SHRs is caused by the genetic background of animals or by high blood pressure, we examined the effect of treatment with four pharmacologically different species of antihypertensive drugs for 2 wk. After normalization of blood pressure of SHRs by treatment with each antihypertensive drug, PDGF A-chain mRNA levels in VSMCs of SHRs were decreased to almost the same levels as in WKY rats. RT Recent study (45) showed that a low concentration (4.2 pM) of PDGF-AA had mitogenic activity for cultured VSMCs. A recent report (12) showed that biological activity of (40) and levels of some transcription factors such as Egr-l in VSMCs were equivalent in the two strains in the present study, it is unlikely that these approximately twofold increases in Spl and AP-2 in VSMCs of SHRs were caused simply by nonspecific increases in protein synthesis. Furthermore, we found that after lowering of blood pressure by antihypertensive treatment, Spl level in VSMCs of SHRs was also decreased, although AP-2 level was not. These results suggest that the observed increase in Spl level in VSMCs of SHRs is associated with high blood pressure, but not with genetic background of the rat strains. In contrast, increases in AP-2 in these cells may be caused the genetic background of the rat strains, although we do not know the mechanisms for this effect at present.
After lowering blood pressure by antihypertensive treatments, Spl level in VSMCs of SHRs was decreased with a concomitant decrease in PDGF A-chain mRNA level. Lin et al. (50) found that the triple contiguous Spl binding sites between -150 and -33 in the promoter region of PDGF A-chain gene have > 80% of this gene's promoter activity in cultured cells. Courey et al. (51) showed by cotransfection analysis that promoter activity of SpI binding sites in the promoter region increased proportionally as SpI concentration was increased. They also showed that Spl can act not only as a proximal promoter factor but also as an enhancer binding factor (18) by Spl-Spl interactions. From these observations, the present results suggest that Spl may mediate the transcriptional activation of PDGF A-chain gene induced by high blood pressure in VSMCs. Additionally, because (a) Spl activates many other genes which may alter PDGF A-chain gene expression and (b) unknown transcription factors which activate the transcription of PDGF A-chain gene may be present in VSMCs, further investigation is needed to determine these possibilities.
Enalapril treatment for 2 and 4 wk decreased SRF (p67SRF) levels in VSMCs of SHRs. SRF is induced by stimulation of serum or protein kinase C activation (35, 37) , and it regulates transcription of genes such as c-fos and PDGF A-chain by forming ternary complexes as SRE/p67SRF/p62TCF (52) . An- giotensin-converting enzyme inhibitors reduce levels of A II within aortic tissue (53) , and A II can stimulate protein kinase C activity in VSMCs (54) . These findings suggest that a decrease in levels of A II in aortic medial layers after enalapril treatment may induce a decrease in SRF levels in VSMCs through downregulation of protein kinase C activity. Further study using angiotensin receptor antagonists will allow determination of the association of A II with regulation of SRF in VSMCs.
In conclusion, levels of PDGF A-chain mRNA and the related transcription factor Spl are increased in hypertrophic VSMCs of SHRs compared with those of normotensive rats in vivo. Antihypertensive treatments decrease the levels of PDGF A-chain mRNA and Spl in VSMCs of SHRs with concomitant reduction of aortic vascular hypertrophy. These results suggest that an autocrine mechanism inducing PDGF A-chain gene expression by high blood pressure in VSMCs of SHRs may play a role in enhancement of hypertensive vascular hypertrophy, and that an increase in availability of Spl in VSMCs induced by high blood pressure may mediate the elevation of PDGF Achain gene expression in these cells.
